Mydecine Innovations Group Stock Buy Hold or Sell Recommendation

MYCOF Stock  USD 0.01  0  25.00%   
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Mydecine Innovations Group is 'Strong Sell'. Macroaxis provides Mydecine Innovations buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MYCOF positions.
  
Check out Mydecine Innovations Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
Note, we conduct extensive research on individual companies such as Mydecine and provide practical buy, sell, or hold advice based on investors' constraints. Mydecine Innovations Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Execute Mydecine Innovations Buy or Sell Advice

The Mydecine recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Mydecine Innovations Group. Macroaxis does not own or have any residual interests in Mydecine Innovations Group or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Mydecine Innovations' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Mydecine InnovationsBuy Mydecine Innovations
Strong Sell

Market Performance

OKDetails

Volatility

Out of controlDetails

Hype Condition

Under hypedDetails

Current Valuation

Fairly ValuedDetails

Odds Of Distress

HighDetails

Economic Sensitivity

Moves completely opposite to the marketDetails

Analyst Consensus

Not AvailableDetails

Reporting Quality (M-Score)

InapplicableDetails
For the selected time horizon Mydecine Innovations Group has a Mean Deviation of 24.43, Semi Deviation of 20.71, Standard Deviation of 34.32, Variance of 1177.62, Downside Variance of 1093.86 and Semi Variance of 428.74
We provide investment recommendation to complement the last-minute expert consensus on Mydecine Innovations Group. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time. To make sure Mydecine Innovations is not overpriced, please verify all Mydecine Innovations Group fundamentals, including its price to sales, debt to equity, market capitalization, as well as the relationship between the net income and earnings per share . As Mydecine Innovations appears to be a penny stock we also strongly suggest to check its price to sales numbers.

Mydecine Innovations Trading Alerts and Improvement Suggestions

Mydecine Innovations is way too risky over 90 days horizon
Mydecine Innovations has some characteristics of a very speculative penny stock
Mydecine Innovations appears to be risky and price may revert if volatility continues
Mydecine Innovations has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 7.49 K. Net Loss for the year was (28.9 M) with profit before overhead, payroll, taxes, and interest of 7.49 K.
Mydecine Innovations Group has accumulated about 324.15 K in cash with (24.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Mydecine Innovations Returns Distribution Density

The distribution of Mydecine Innovations' historical returns is an attempt to chart the uncertainty of Mydecine Innovations' future price movements. The chart of the probability distribution of Mydecine Innovations daily returns describes the distribution of returns around its average expected value. We use Mydecine Innovations Group price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Mydecine Innovations returns is essential to provide solid investment advice for Mydecine Innovations.
Mean Return
4.39
Value At Risk
-37.5
Potential Upside
55.56
Standard Deviation
34.32
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Mydecine Innovations historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Mydecine Innovations Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Mydecine Innovations or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Mydecine Innovations' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Mydecine pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
4.56
β
Beta against Dow Jones-5.34
σ
Overall volatility
33.26
Ir
Information ratio 0.13

Mydecine Innovations Volatility Alert

Mydecine Innovations Group is showing large volatility of returns over the selected time horizon. Mydecine Innovations Group is a penny stock. Even though Mydecine Innovations may be a good instrument to invest, many penny pink sheets are speculative instruments that are subject to artificial stock promotions. Please make sure you fully understand upside and downside scenarios of investing in Mydecine Innovations Group or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings,sudden promotions and many other similar artificial hype indicators. We also encourage traders to check work history of company executives before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Mydecine instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Mydecine Innovations Fundamentals Vs Peers

Comparing Mydecine Innovations' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Mydecine Innovations' direct or indirect competition across all of the common fundamentals between Mydecine Innovations and the related equities. This way, we can detect undervalued stocks with similar characteristics as Mydecine Innovations or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Mydecine Innovations' fundamental indicators could also be used in its relative valuation, which is a method of valuing Mydecine Innovations by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Mydecine Innovations to competition
FundamentalsMydecine InnovationsPeer Average
Return On Equity-12.24-0.31
Return On Asset-1.76-0.14
Current Valuation8.64 M16.62 B
Shares Outstanding13.01 M571.82 M
Shares Owned By Insiders8.71 %10.09 %
Price To Book23.41 X9.51 X
Price To Sales677.59 X11.42 X
Revenue7.49 K9.43 B
Gross Profit7.49 K27.38 B
EBITDA(23.14 M)3.9 B
Net Income(28.9 M)570.98 M
Cash And Equivalents324.15 K2.7 B
Cash Per Share0.04 X5.01 X
Total Debt4.35 M5.32 B
Debt To Equity0.06 %48.70 %
Current Ratio1.26 X2.16 X
Book Value Per Share(0.36) X1.93 K
Cash Flow From Operations(24.05 M)971.22 M
Earnings Per Share(4.68) X3.12 X
Target Price140.0
Number Of Employees1118.84 K
Beta3.42-0.15
Market Capitalization5.94 M19.03 B
Total Asset7.58 M29.47 B
Z Score-9.38.72
Net Asset7.58 M

Mydecine Innovations Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Mydecine . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Mydecine Innovations Buy or Sell Advice

When is the right time to buy or sell Mydecine Innovations Group? Buying financial instruments such as Mydecine Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Mydecine Innovations in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Raw Materials Thematic Idea Now

Raw Materials
Raw Materials Theme
Companies that are involved with the development and processing of raw materials such as silver or forestry. The Raw Materials theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Raw Materials Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Mydecine Pink Sheet

Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.